EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Effect of the Combination of Concomitant Drugs on Efficacy of Immune Checkpoint Inhibitors in Non‐Small Cell Lung Cancer

Masafumi Saiki iD, Kazuho Takusagawa, Nozomu Takahashi iD, Kenta Homma, Tsukasa Satoh iD, Satoshi Furuya iD, So Shimamura, Chisa Omori, Hiroki Ohkoshi iD, Yuki Hoshino iD, Yoshinori Uchida iD, Shinnosuke Ikemura iD und 1 weitere

Cancer Reports · 2025

DOI: 10.1002/cnr2.70399 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Reports, 2025. Verfasst von Masafumi Saiki und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory Medicine, Graduate School of Medicine, University of Yamanashi, Chuo, Yamanashi, Japan. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Immune Checkpoint Inhibitors, Lung Neoplasms, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Emerging evidence indicates that baseline use of certain concomitant drugs may affect the efficacy of immune checkpoint inhibitors (ICIs), including PD‐1, PD‐L1, and CTLA‐4 inhibitors, in patients with cancer. However, most previous studies have evaluated individual drug classes in isolation, without considering potential interactions among multiple drugs.

Aims

This study aimed to evaluate the individual and combined effects of commonly prescribed concomitant drugs on the efficacy and safety of ICI‐based therapy in patients with non‐small cell lung cancer (NSCLC).

Methods

We conducted a retrospective analysis of 124 patients with advanced or recurrent NSCLC who received first‐line ICI‐based treatments at a single institution. Drug exposure at treatment initiation was assessed for proton pump inhibitors (PPIs), low‐dose aspirin, non‐steroidal anti‐inflammatory drugs, statins, biguanides, antibiotics, and probiotics. Associations with progression‐free survival (PFS), overall survival (OS), and immune‐related adverse events (irAEs) were analyzed using multivariate Cox regression models.

Results

PPI use was independently associated with shorter PFS (HR: 2.44, p < 0.001) and OS (HR: 2.04, p = 0.01). In contrast, low‐dose aspirin use was independently associated with longer PFS (HR: 0.31, p = 0.01). Patients receiving both PPIs and aspirin had longer PFS and OS compared to those receiving PPIs alone, although the differences were not statistically significant. No consistent associations were observed for other drugs. The incidence of irAEs was not significantly affected by concomitant drug use.

Conclusion

PPI use at baseline may be associated with reduced efficacy of ICI therapy in NSCLC patients. In contrast, low‐dose aspirin use was independently associated with improved PFS, and may potentially mitigate the negative effects of PPIs. These findings underscore the importance of considering concomitant drug use when initiating ICI treatment. Prospective studies are needed to validate these observations and clarify underlying mechanisms.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungImmune Checkpoint InhibitorsLung NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsHumansMaleFemaleRetrospective StudiesMiddle AgedAgedProton Pump InhibitorsAspirinProgression-Free SurvivalAdultAged, 80 and overDrug InteractionsNeoplasm Recurrence, Local

Stichwörter der Autor:innen

concomitant drugsimmune checkpoint inhibitornon‐small cell lung cancerproton pump inhibitor

Substanzen

Immune Checkpoint InhibitorsProton Pump InhibitorsAspirin

Autor:innen und Institutionen

  • Department of Respiratory Medicine, Graduate School of Medicine, University of Yamanashi, Chuo, Yamanashi, Japan.

ORCID-Profile: Masafumi Saiki, Nozomu Takahashi, Tsukasa Satoh, Satoshi Furuya, Hiroki Ohkoshi, Yuki Hoshino, Yoshinori Uchida, Shinnosuke Ikemura, Kenzo Soejima

Förderung

  • Japan Society for the Promotion of Science

Zitieren

APA

Saiki, M., Takusagawa, K., Takahashi, N., Homma, K., Satoh, T., Furuya, S., Shimamura, S., Omori, C., Ohkoshi, H., Hoshino, Y., Uchida, Y., Ikemura, S., & Soejima, K. (2025). Effect of the Combination of Concomitant Drugs on Efficacy of Immune Checkpoint Inhibitors in Non‐Small Cell Lung Cancer. Cancer Reports. https://doi.org/10.1002/cnr2.70399

Vancouver

Saiki M, Takusagawa K, Takahashi N, Homma K, Satoh T, Furuya S, et al. Effect of the Combination of Concomitant Drugs on Efficacy of Immune Checkpoint Inhibitors in Non‐Small Cell Lung Cancer. Cancer Reports. 2025. doi:10.1002/cnr2.70399

BibTeX
@article{Saiki2025,
  author = {Saiki, Masafumi and Takusagawa, Kazuho and Takahashi, Nozomu and Homma, Kenta and Satoh, Tsukasa and Furuya, Satoshi and Shimamura, So and Omori, Chisa and Ohkoshi, Hiroki and Hoshino, Yuki and Uchida, Yoshinori and Ikemura, Shinnosuke and Soejima, Kenzo},
  title = {Effect of the Combination of Concomitant Drugs on Efficacy of Immune Checkpoint Inhibitors in Non‐Small Cell Lung Cancer},
  journal = {Cancer Reports},
  year = {2025},
  doi = {10.1002/cnr2.70399}
}
Kostenlos starten →